{"id":35835,"date":"2026-09-09T09:00:00","date_gmt":"2026-09-09T13:00:00","guid":{"rendered":"https:\/\/www.spotyellow.com\/blog\/?p=35835"},"modified":"2026-09-09T08:11:01","modified_gmt":"2026-09-09T12:11:01","slug":"hrt-breast-cancer-risk","status":"publish","type":"post","link":"https:\/\/www.spotyellow.com\/blog\/hrt-breast-cancer-risk\/","title":{"rendered":"HRT and Breast Cancer Risk: What the Numbers Actually Say"},"content":{"rendered":"<p><strong>The short answer:<\/strong> For most women, hormone replacement therapy (HRT) adds a small amount to breast cancer risk, and it is best understood as extra cases per 1,000 women, not as a scary percentage. Estrogen-only HRT (oestrogen-only in UK spelling) carries little or no increased risk, and after a hysterectomy it may slightly lower it. Combined HRT, estrogen plus a progestogen (progestin in the US), adds roughly 5 to 20 extra cases per 1,000 women over five years depending on the regimen, per NICE NG23 (2024). That risk rises with longer use and largely falls once you stop. To put it in scale: drinking more than a couple of units of alcohol a day, or carrying extra weight, sits in a similar or larger range.<\/p>\n<p>If you have ever typed &#8220;will HRT give me breast cancer&#8221; into a search bar at 2am, you are not being irrational. On the r\/Menopause and r\/Perimenopause forums, this is the single most common fear women name out loud. One recurring theme: &#8220;I want to stop the hot flushes and the brain fog, but is it worth the cancer risk?&#8221; Another: women told by a nervous relative or an old headline that HRT &#8220;gave&#8221; someone breast cancer, and now they are frozen. The fear is real and it deserves real numbers, not reassurance and not scare stories. This post gives you the evidence so you can decide with a practitioner.<\/p>\n<p>This is the breast-cancer-specific deep dive. For the wider safety picture, including clots and heart health, see our companion guide on <a href=\"https:\/\/www.spotyellow.com\/blog\/is-hrt-safe-2026-evidence\/\">whether HRT is safe<\/a>.<\/p>\n<h2>Does HRT cause breast cancer?<\/h2>\n<p>HRT does not &#8220;cause&#8221; breast cancer in the way that word usually lands. The evidence points to a small increase in risk for combined HRT, not a switch that gets flipped. According to the Collaborative Group on Hormonal Factors in Breast Cancer, whose 2019 Lancet meta-analysis pooled data on almost 144,000 women with breast cancer, the association is real but modest and depends heavily on the type and duration of HRT.<\/p>\n<p>The most useful way to hold this is absolute risk, meaning the actual number of women affected, rather than relative risk, meaning a percentage change. A headline saying &#8220;HRT raises breast cancer risk by 30 percent&#8221; sounds alarming. But 30 percent of a small baseline number is still a small number. NICE NG23 (2024) deliberately expresses the risk as extra cases per 1,000 women for exactly this reason.<\/p>\n<p>For context, roughly 23 women in every 1,000 not taking HRT would be expected to develop breast cancer over a five-year window at these ages, per NICE NG23 (2024). The HRT-related figures below are added on top of that baseline, not multiplied.<\/p>\n<h2>How big is the actual breast cancer risk with HRT?<\/h2>\n<p>The extra risk is small and depends on which HRT you take. NICE NG23 (2024) estimates, for women aged 50 to 69 using HRT for five years, roughly:<\/p>\n<ul>\n<li>About 5 extra cases per 1,000 women on estrogen-only HRT.<\/li>\n<li>About 14 extra cases per 1,000 women on sequential combined HRT (progestogen part of each month).<\/li>\n<li>About 20 extra cases per 1,000 women on continuous combined HRT (daily progestogen).<\/li>\n<\/ul>\n<p>These numbers roughly double if HRT is used for ten years rather than five, per NICE NG23 (2024). The 2019 Lancet meta-analysis found a similar shape: risk that scales with duration and is far smaller for shorter use. Note that these are averages across large populations, not a prediction for any one woman.<\/p>\n<h2>Is estrogen-only HRT safer for breast cancer?<\/h2>\n<p>Yes, on the breast cancer question specifically, estrogen-only HRT carries little or no increased risk. This is why the NICE figure above is so much lower for estrogen alone. Estrogen-only HRT is generally only prescribed to women who have had a hysterectomy, because unopposed estrogen raises the risk of womb cancer in women who still have a uterus.<\/p>\n<p>The evidence here is striking. In the long-term follow-up of the Women&#8217;s Health Initiative published in JAMA (2020), the estrogen-alone group actually had lower breast cancer incidence and lower breast cancer mortality than placebo. That is the opposite of the 2002 scare. It does not mean estrogen protects everyone, but it firmly closes the idea that estrogen-only HRT is a major breast cancer driver.<\/p>\n<p>For a fuller look at why the hormone formulation matters, see our guide on <a href=\"https:\/\/www.spotyellow.com\/blog\/body-identical-vs-synthetic-hrt\/\">body-identical versus synthetic HRT<\/a>.<\/p>\n<h2>Why does the type of progestogen matter?<\/h2>\n<p>The progestogen, not the estrogen, is the part of combined HRT most linked to the small extra breast cancer risk. And not all progestogens behave the same. Body-identical micronised progesterone appears lower-risk than older synthetic progestins.<\/p>\n<p>The French E3N cohort found that estrogen combined with micronised progesterone was not associated with a meaningfully raised breast cancer risk over shorter-term use, whereas synthetic progestins carried a higher relative risk, per the British Menopause Society&#8217;s reading of that evidence. The BMS notes the absolute difference between progestogen types is small, particularly for short-term use, but it is a real and reasonable thing to raise with a practitioner. If breast cancer risk weighs heavily on you, ask specifically which progestogen you are being offered.<\/p>\n<h2>Does the breast cancer risk go away when I stop HRT?<\/h2>\n<p>Largely, yes, and this is one of the most reassuring findings. The extra risk from combined HRT declines after you stop, and for women who used combined HRT for less than five years, the excess risk had essentially disappeared five years after stopping, per the 2019 Lancet meta-analysis.<\/p>\n<p>For longer use, some excess risk can persist for more than ten years after stopping, per the same analysis, which is one reason duration matters so much in the conversation. The takeaway is that HRT risk is not a permanent stamp. It tracks with current and recent use, and it eases once treatment ends. This is very different from a one-way, cumulative danger.<\/p>\n<h2>How does HRT risk compare to everyday things?<\/h2>\n<p>This is where perspective helps most. The extra breast cancer risk from combined HRT sits in a similar range to several everyday factors that rarely cause the same fear. NICE NG23 (2024) and Cancer Research UK frame the comparison to help women weigh it honestly rather than in isolation.<\/p>\n<table>\n<thead>\n<tr>\n<th>Factor<\/th>\n<th>Approximate extra breast cancer cases per 1,000 women (ages ~50-69, over 5 years)<\/th>\n<th>Source<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Baseline (no HRT)<\/td>\n<td>~23 cases total expected<\/td>\n<td>NICE NG23 (2024)<\/td>\n<\/tr>\n<tr>\n<td>Estrogen-only HRT, 5 years<\/td>\n<td>About 5 extra<\/td>\n<td>NICE NG23 (2024)<\/td>\n<\/tr>\n<tr>\n<td>Combined HRT (continuous), 5 years<\/td>\n<td>About 20 extra<\/td>\n<td>NICE NG23 (2024)<\/td>\n<\/tr>\n<tr>\n<td>Drinking more than 2 units of alcohol a day<\/td>\n<td>In a broadly similar range to combined HRT<\/td>\n<td>NICE NG23 (2024); Cancer Research UK<\/td>\n<\/tr>\n<tr>\n<td>Being overweight or obese after menopause<\/td>\n<td>In a broadly similar or larger range<\/td>\n<td>NICE NG23 (2024); Cancer Research UK<\/td>\n<\/tr>\n<tr>\n<td>Physical inactivity<\/td>\n<td>A measurable added risk<\/td>\n<td>Cancer Research UK<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The point is not to dismiss the HRT number. It is real. The point is that a woman worried about 20 extra cases per 1,000 from HRT may also be drinking two glasses of wine most evenings, which sits in a comparable range and gets none of the same anxiety, per Cancer Research UK. Seeing the full board makes the decision clearer, not scarier.<\/p>\n<h2>What went wrong with the WHI headlines in the early 2000s?<\/h2>\n<p>The fear most women carry traces back to one moment: the 2002 Women&#8217;s Health Initiative headlines. When the WHI combined-HRT arm was halted early, coverage announced that HRT raised breast cancer risk, and prescriptions fell off a cliff worldwide. The reporting was blunt where the data was nuanced.<\/p>\n<p>Several things were later reinterpreted. The WHI studied older women, average age 63, many years past menopause, using one specific older synthetic progestin, not the range of modern regimens. The estrogen-only arm, largely lost in the 2002 noise, later showed lower breast cancer incidence and mortality, per JAMA (2020). The relative-risk framing also inflated the sense of danger, because a percentage rise on a small baseline is still a small number of women.<\/p>\n<p>None of this means the WHI was worthless. It means the early headlines flattened a complex result into a single scary sentence, and that sentence outlived the correction. Current guidance from NICE, the British Menopause Society, and The Menopause Society reflects the reinterpreted picture, not the 2002 version.<\/p>\n<h2>Who needs extra caution with HRT and breast cancer?<\/h2>\n<p>Some women do sit in a higher-caution group, and this is exactly the conversation to have with a practitioner rather than the internet. A personal history of breast cancer is the clearest reason for caution. HRT is not usually recommended for women with a current or past breast cancer, and any exceptions are specialist decisions, per the British Menopause Society.<\/p>\n<p>A strong family history, certain genetic factors, or high personal baseline risk may also shift the balance. This does not automatically rule HRT out, but it changes the weighing. Vaginal estrogen, used locally for dryness and urinary symptoms, is a separate and much lower-dose treatment and is often viewed differently from systemic HRT, though it should still be discussed individually.<\/p>\n<h2>How do I have an honest conversation with a practitioner?<\/h2>\n<p>Bring the specifics, not just the fear. A useful conversation covers your symptoms and how much they affect daily life, your personal and family history, and the exact HRT type and duration on offer. You can reasonably ask which progestogen is being used and why, and how the risk applies to you rather than to a population average.<\/p>\n<p>Yellow exists to make that preparation easier. On spotyellow.com you can read plain-language explainers before an appointment, and if you want to find a menopause-literate practitioner, our <a href=\"https:\/\/www.spotyellow.com\/directory\/\">directory<\/a> is a starting point. For the practical steps of getting seen and prescribed, see our guide on <a href=\"https:\/\/www.spotyellow.com\/blog\/how-to-get-hrt-prescription\/\">how to get an HRT prescription<\/a>. The goal is a shared decision, made with real numbers, that fits your body and your life.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<h3>Will HRT give me breast cancer?<\/h3>\n<p>No single treatment &#8220;gives&#8221; you breast cancer. Combined HRT adds a small extra risk, roughly 5 to 20 extra cases per 1,000 women over five years depending on the regimen, per NICE NG23 (2024). That is added to a baseline risk everyone already carries. Estrogen-only HRT adds little or none.<\/p>\n<h3>Is estrogen-only HRT safer for the breasts?<\/h3>\n<p>Yes, on breast cancer specifically. Estrogen-only HRT carries little or no increased risk, and WHI follow-up in JAMA (2020) found lower breast cancer incidence and mortality in the estrogen-alone group. It is generally only prescribed after a hysterectomy, because unopposed estrogen raises womb cancer risk in women with a uterus.<\/p>\n<h3>Does the breast cancer risk go away when I stop HRT?<\/h3>\n<p>Largely, yes. For women who used combined HRT for under five years, the excess risk had essentially disappeared five years after stopping, per the 2019 Lancet meta-analysis. Longer use can leave a smaller residual risk for over ten years. The risk tracks current and recent use, not a permanent stamp.<\/p>\n<h3>Does the type of progestogen change my risk?<\/h3>\n<p>It can. Micronised progesterone (body-identical) appears lower-risk than older synthetic progestins for breast cancer, based on the E3N cohort as read by the British Menopause Society. The absolute difference is small, especially short-term, but it is a fair and specific thing to ask your practitioner about.<\/p>\n<h3>Is HRT riskier than drinking alcohol?<\/h3>\n<p>Not dramatically. The extra breast cancer risk from combined HRT sits in a broadly similar range to drinking more than two units of alcohol a day, and to carrying excess weight after menopause, per NICE NG23 (2024) and Cancer Research UK. Seeing HRT next to everyday factors helps put its size in perspective.<\/p>\n<h3>I had breast cancer before. Can I take HRT?<\/h3>\n<p>HRT is not usually recommended after breast cancer, and any exception is a specialist decision, per the British Menopause Society. Non-hormonal options exist for symptoms, and local vaginal estrogen for dryness is sometimes considered separately at very low doses. This is a case for an individualised discussion, not a general rule.<\/p>\n<h2>Further Reading<\/h2>\n<ul>\n<li>NICE, Menopause: identification and management (NG23), updated 2024, including the HRT discussion aid on breast cancer and other conditions.<\/li>\n<li>Collaborative Group on Hormonal Factors in Breast Cancer, &#8220;Type and timing of menopausal hormone therapy and breast cancer risk,&#8221; The Lancet, 2019.<\/li>\n<li>Women&#8217;s Health Initiative, &#8220;Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up,&#8221; JAMA, 2020.<\/li>\n<li>British Menopause Society, consensus statements on HRT and breast cancer risk and on progestogens.<\/li>\n<li>Cancer Research UK, breast cancer risk factors, including alcohol, body weight, and physical activity.<\/li>\n<\/ul>\n<p><em>This article is for general information and education about menopause and is not medical advice. It is not a recommendation to take or avoid HRT. Talk with a qualified practitioner about your own history, risk factors, and options before making any decision.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Does HRT cause breast cancer? The honest, evidence-led answer: how small the extra risk really is, why estrogen-only differs, and how it compares to alcohol and weight.<\/p>\n","protected":false},"author":1,"featured_media":35853,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"slim_seo":{"title":"HRT and Breast Cancer Risk: What the Numbers Actually Say - Yellow","description":"Does HRT cause breast cancer? The honest, evidence-led answer: how small the extra risk really is, why estrogen-only differs, and how it compares to alcohol and"},"_slim_seo_primary_term_category":0,"_slim_seo_primary_term_post_tag":0,"_slim_seo_primary_term_post_template":0,"_slim_seo_primary_term_top_category":0,"footnotes":""},"categories":[78],"tags":[],"post_template":[],"top_category":[],"class_list":["post-35835","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-treatment-options"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/posts\/35835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/comments?post=35835"}],"version-history":[{"count":3,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/posts\/35835\/revisions"}],"predecessor-version":[{"id":36101,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/posts\/35835\/revisions\/36101"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/media\/35853"}],"wp:attachment":[{"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/media?parent=35835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/categories?post=35835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/tags?post=35835"},{"taxonomy":"post_template","embeddable":true,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/post_template?post=35835"},{"taxonomy":"top_category","embeddable":true,"href":"https:\/\/www.spotyellow.com\/blog\/wp-json\/wp\/v2\/top_category?post=35835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}